Tumblr Fave Likes Y...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$27.56 0.12 | 0.44%
05/20/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -106.01M | -57.65M | -43.52M | -47.59M |
| Operating Gains/Losses | -11.82M | 3.50M | 3.22M | 4.40M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 1.36M | 12.65M | -8.08M | -1.86M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.74M | -3.51M | -3.18M | 9.90M |
| (Decrease) Increase In Other Current Liabilities | -3.59M | 2.46M | -4.86M | -808.00K |
| (Increase) Decrease In Other Working Capital | -6.78M | -70.26M | -60.70M | -58.17M |
| Other Non-Cash Items | 2.15M | 17.88M | 19.83M | 20.63M |
| Net Cash From Continuing Operations | -115.61M | -87.07M | -84.34M | -72.14M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -115.61M | -87.07M | -84.34M | -72.14M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 413.04M | 504.57M |
| Purchases of Property, Plant & Equipment | -8.35M | -1.29M | -4.73M | -4.95M |
| Acquisitions | 0.00 | 0.00 | 0.00 | -10.00M |
| Purchases of Short-Term Investments | 0.00 | -293.12M | -390.47M | -481.34M |
| Other Cash from Investing Activities | -162.00K | 0.00 | 0.00 | 6.15M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 3.37M | 81.96M | 17.84M | 14.43M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 93.77M | 738.00K | 3.66M | 3.51M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | -359.00K | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 93.41M | 738.00K | 3.66M | 3.51M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | -29.00K | -121.00K |
| Net Change in Cash & Cash Equivalents | -18.82M | -4.37M | -62.87M | -54.32M |
Portfolios with ALNY
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe #1 Growth Fund To Make ...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
Latest ALNY Headlines from TheStreet
- Cramer's Top Stock Picks: CAT CAG MHR ISS ALNY SGMO KIM 04.04.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Risk vs. Reward 04.03.13 | 08:04 pm
- 'Mad Money' Lightning Round: I Like Bank of America 02.23.13 | 06:02 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 02.22.13 | 08:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Alnylam Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript) 09.12.12 | 10:09 am
- Alnylam Pharmaceuticals CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.06.12 | 10:08 pm
- 5 Stocks Insiders Love Right Now 02.24.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.15.12 | 02:02 pm
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
Press Releases for ALNY
- Alnylam Initiates Phase I Clinical Study For ALN-TTRsc, A Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) - Business Wire 03.18.13 | 08:03 am
- Alnylam To Webcast Presentation At Barclays Global Healthcare Conference - Business Wire 03.05.13 | 04:03 pm
- Alnylam To Webcast Presentation At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 04:02 pm
- Corporate Leaders Receive Thirteenth Annual Emerald Asset Management “E-3 Awards” - Business Wire 02.11.13 | 10:02 am
- Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.07.13 | 04:02 pm
- Alnylam To Webcast Presentation At Upcoming Investor Conferences - Business Wire 02.05.13 | 04:02 pm
- Over 25 Companies To Present At Emerald Groundhog Day Investment Forum - Business Wire 02.05.13 | 10:02 am
- The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia - Business Wire 02.04.13 | 06:02 am
- Alnylam To Webcast Conference Call Discussing Fourth Quarter And 2012 Financial Results - Business Wire 01.31.13 | 04:01 pm
- Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP, An RNAi Therapeutic For The Treatment Of Liver Cancer - Business Wire 01.30.13 | 08:01 am
Partner Headlines for ALNY
- Alnylam-Tekmira Settle Up - Analyst Blog - Zacks 11.19.12 | 07:11 pm
- Revenues Decline at Alnylam - Analyst Blog - Zacks 11.07.12 | 09:11 am
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam - Benzinga 10.23.12 | 01:10 pm
- Alnylam-ISIS Venture Prices IPO - Analyst Blog - Zacks 10.05.12 | 06:10 pm
- Alnylam Presents Data on ALN-RSV01 - Analyst Blog - NASDAQ 09.06.12 | 11:09 pm
- Alnylam Presents Data on ALN-RSV01 - Analyst Blog - Zacks 09.06.12 | 07:09 pm
- Alnylam & Monsanto Collaborate - Analyst Blog - NASDAQ 08.29.12 | 09:08 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - NASDAQ 08.22.12 | 11:08 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - Zacks 08.22.12 | 07:08 pm
- Biogen Inks Deal with Regulus - Analyst Blog - NASDAQ 08.16.12 | 10:08 pm
